Pharmaceutical sponsors are embedding continuous biosensors directly into Phase II and Phase III oncology clinical trial protocols. The transition provides continuous longitudinal data streams, replacing traditional intermittent clinic visits.
Data Fidelity and Patient Retention
Continuous monitoring enables early detection of adverse events, lowering trial dropout rates by an estimated 22%. Regulatory agencies are establishing standardized guidelines to validate real-world sensor telemetry for primary endpoint evaluations.